Bicycle Therapeutics ( NASDAQ:BCYC ) First Quarter 2024 Results Key Financial Results Revenue: US$19.5m (up 299% from...
Comparison with Analyst Estimates and Strategic Developments
CAMBRIDGE, England & BOSTON, May 02, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2024.